Punica granatum (pomegranate) juice provides an HIV-1 entry inhibitor and candidate topical microbicide

Annals of the New York Academy of Sciences

Volumn 1056, Issue , 2005, Pages 311-327

  Neurath, A Robert ^a,b   Strick, Nathan ^a   Li, Yun Yao ^a   Debnath, Asim K ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b Lindsley F Kimball Res Institute   (United States)

Author keywords

CD4; Coreceptors for HIV 1; CXCR4 CCR5; Human immunodeficiency virus (HIV 1); Microbicides; Pomegranate juice; Punica granatum; Receptors for HIV 1; Virus entry inhibitors

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; MICROBICIDE; PJ S21; PUNICA GRANATUM EXTRACT; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIMICROBIAL ACTIVITY; CONFERENCE PAPER; DRUG DOSAGE FORM; DRUG MARKETING; FOOD SAFETY; FRUIT JUICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; INHIBITION KINETICS; NONHUMAN; POMEGRANATE; STANDARDIZATION; VIRUS INHIBITION; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LYTHRACEAE; PUNICA GRANATUM; ZEA MAYS;

EID: 29744443499     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1352.015     Document Type: Conference Paper

References (109)

1. UNAIDS/WHO. 2004. Global summary of the HIV and AIDS epidemic. December 2004. [http://www.unaids.org/EN/resources/epidemiology/epicore.asp].
2. WHO/SEARO CDS HIV/AIDS. 2004. HIV/AIDS Facts and Figures: Facts about HIV/AIDS-Global. [http://w3.whosea.org/en/Section10/Section18/Section348.htm].
3. SHATTOCK, R.J. & J.P. MOORE. 2003. Inhibiting sexual transmission of HIV-1 infection. Nat. Rev. Microbiol. 1: 25-34.
4. PILCHER, C.D. et al. 2004. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189: 1785-1792.
5. STONE, A. 2002. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat. Rev. Drug. Discovery 1: 977-985.
6. SHATTOCK, R. & S. SOLOMON. 2004. Microbicides-aids to safer sex. Lancet 363: 1002-1003.
7. BROWN, H. 2004. Marvellous microbicides. Intravaginal gels could save millions of lives, but first someone has to prove that they work. Lancet 363: 1042-1043.
8. MOORE, J.P. & R.W. DOMS. 2003. The entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. USA 100: 10598-10602.
9. PIERSON, T.C. & R.W. DOMS. 2003. HIV-1 entry inhibitors: new targets, novel therapies. Immunol. Lett. 85: 113-118.
10. DAVIS, C.W. & R.W. DOMS. 2004. HIV Transmission: closing all the doors. J. Exp. Med. 199: 1037-1040.
11. HU, Q. et al. 2004. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J. Exp. Med. 199: 1065-1075.
12. FICHOROVA, R.N., L.D. TUCKER & D.J. ANDERSON. 2001. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J. Infect. Dis. 184: 418-428.
13. FICHOROVA, R.N. et al. 2004. Interleukin (IL)-1, IL-6 and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol. Reprod. 71: 761-769.
14. WEISS, R. 2001. AIDS: unbeatable 20 years on. Lancet 357: 2073-2074.
15. NEURATH, A.R. et al. 1995. Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis. J. Mol. Recognition 8: 304-316.
16. JIANG, S. et al. 1996. Chemically modified bovine-lactoglobulin blocks uptake of HIV-1 by colon- and cervix-derived epithelial cell lines. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13: 461-462.
17. NEURATH, A.R. et al. 1996. A herpesvirus inhibitor from bovine whey. Lancet 347: 1703.
18. NEURATH, A.R. et al. 1997. 3-Hydroxyphtaloyl-lactoglobulin: I. Optimization of production and comparison with other compounds considered for chemoprophylaxis of mucosally transmitted human immunodeficiency virus type 1. Antivir. Chem. Chemother. 8: 131-139.
19. NEURATH, A.R. et al. 1996. Bovine-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV. Nat. Med. 2: 230-234.
20. JIANG, S. et al. 1997. Virucidal and antibacterial activities of 3-HP-LG. In Vaccines 97: Molecular Approaches to the Control of Infectious Diseases. F. Brown et al. Eds. :327-330. Cold Spring Harbor Laboratory Press. New York.
21. NEURATH, A.R. et al. 1997. 3-Hydroxyphtaloyl-lactoglobulin: II. Anti-human immunodeficiency virus type 1 activity in in vitro environments relevant to prevention of sexual transmission of the virus. Antivir. Chem. Chemother. 8: 141-148.
22. NEURATH, A.R., N. STRICK & Y.-Y. LI. 1998. 3-Hydroxyphthaloyl- lactoglobulin: III. Antiviral activity against herpesviruses. Antivir. Chem. Chemother. 9: 177-184.
23. KOKUBA, H., L. AURELIAN & A.R. NEURATH. 1998. 3-Hydroxyphthaloyl -lactoglobulin: IV. Antiviral activity in the mouse model of genital herpesvirus infection. Antivir. Chem. Chemother. 9: 353-357.
24. WYAND, M.S. et al. 1999. Effect of 3-hydroxyphthaloyl-lactoglobulin on vaginal transmission of simian immunodeficiency virus in rhesus monkeys. Antimicrob. Agents Chemother. 43: 978-980.
25. FDA's CENTER FOR FOOD SAFETY AND APPLIED NUTRITION (CFSCAN). 2004. Commonly asked questions about BSE in products regulated by PDA's Center for Food Safety and Applied Nutrition (CFSAN) [http://vm.cfsan.fda.gov/~comm/bse- faq.html%20].
26. CHIU, Y.-Y. 2002. An Update CDER Biotechnology BSE Activities: BSE in manufacturing FDA regulatory actions. [http://www.temple.edu/pharmacy_QARA/ fda_conf_Chiu.ppt].
27. U.S. FOOD AND DRUG ADMINISTRATION CfFSaAN. 2001. Agency response letter GRAS Notice No. GRN 000077. [http://vm.cfsan.fda.gov/~rdb/opa-g077.html].
28. CDC NCfID. 2004. Update 2002: Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease. [http://www.cdc.gov/ncidod/diseases/cjd/ bse_cjd.htm].
29. WORLD HEALTH ORGANIZATION. 2002. Bovine spongiform encephalopathy (Fact Sheet No. 113). [http://www.who.int/mediacentre/factsheets/fs113/en/].
30. NEURATH, A.R. et al. 1999. Design of a "microbicide" for prevention of sexually transmitted diseases using"inactive" pharmaceutical excipients. Biologicals 27: 11-21.
31. NEURATH, A.R. et al. 2001. Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect. Dis. 1: 17. [http://www.biomedcentral.com/content/pdf/1471-2334-1-17.pdf].
32. NEURATH, A.R. et al. 2002. Anti-HIV-1 activity of cellulose acetate phthalate: Synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. BMC Infect. Dis. 2: 6. [http://www.biomedcentral.com/content/ pdf/1471-2334-2-6.pdf].
33. NEURATH. A.R., N. STRICK & Y.-Y. LI. 2002. Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. BMC Infect. Dis. 2: 27. [http://www.biomedcentral.com/content/pdf/1471-2334-2-27.pdf].
34. NEURATH, A.R., N. STRICK & Y.-Y. LI. 2003. Water dispersible microbicidal cellulose acetate phthalate film. BMC Infect. Dis. 3: 27. [http://www.biomedcentral.com/content/pdf/1471-2334-3-27.pdf].
35. AVIRAM, M. et al. 2000. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am. J. Clin. Nutr. 71: 1062-1076.
36. PEHOWICH, D.J., A.V. GOMES & J.A. BARNES. 2000. Fatty acid composition and possible health effects of coconut constituents. West Indian Med. J. 49: 128-133.
37. HAMMERSTONE, J.F., S.A. LAZARUS & H.H. SCHMITZ. 2000. Procyanidin content and variation in some commonly consumed foods. J. Nutr. 130: 2086S-2092S.
38. AVIRAM, M. & L. DORNFELD. 2001. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis 158: 195-198.
39. JOSHI, S.S., C.A. KUSZYNSKI & D. BAGCHI. 2001. The cellular and molecular basis of health benefits of grape seed proanthocyanidin extract. Curr. Pharm. Biotechnol. 2: 187-200.
40. LIU, Y. et al. 2001. Citrus pectin: characterization and inhibitory effect on fibroblast growth factor-receptor interaction. J. Agric. Food Chem. 49: 3051-3057.
41. KAPLAN, M. et al. 2001. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J. Nutr. 131: 2082-2089.
42. HOWELL, A.B. 2002. Cranberry proanthocyanidins and the maintenance of urinary tract health. Crit. Rev. Food Sci. Nutr. 42: 273-278.
43. MILBURY, P.E. et al. 2002. Bioavailablility of elderberry anthocyanins. Mech. Ageing Dev. 123:997-1006.
44. WANG, X.H., L. ANDRAE & N. J. ENGESETH. 2002. Antimutagenic effect of various honeys and sugars against Trp-p-1. J. Agric. Food Chem. 50: 6923-6928.
45. SUN, J. et al. 2002. Antioxidant and antiproliferative activities of common fruits. J. Agric. Food Chem. 50: 7449-7454.
46. CAVANAGH, H.M., M. HIPWELL & J.M. WILKINSON. 2003. Antibacterial activity of berry fruits used for culinary purposes. J. Med. Food 6: 57-61.
47. SANCHEZ-MORENO, C. et al. 2003. Anthocyanin and proanthocyanidin content in selected white and red wines. Oxygen radical absorbance capacity comparison with nontraditional wines obtained from highbush blueberry. J. Agric. Food Chem. 51: 4889-4896.
48. POLAGRUT, J.A. et al. 2003. Effects of flavonoid-rich beverages on prostacyclin synthesis in humans and human aortic endothelial cells: association with ex vivo platelet function. J. Med. Food 6: 301-308.
49. GHELDOF, N., X.H. WANG & N.J. ENGESETH. 2003. Buckwheat honey increases serum antioxidant capacity in humans. J. Agric. Food Chem. 51: 1500-1505.
50. AVIRAM, M. et al. 2004. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin. Nutr. 23: 423-433.
51. JIRATANAN, T. & R.H. LIU. 2004. Antioxidant activity of processed table beets (Beta vulgaris var, conditiva) and green beans (Phaseolus vulgaris L.). J. Agric. Food Chem. 52: 2659-2670.
52. HUANO, H.Y. et al. 2004. Antioxidant activities of various fruits and vegetables produced in Taiwan. Int. J. Food Sci. Nutr. 55: 423-429.
53. NINFALI, P. et al. 2005. Antioxidant capacity of vegetables, spices and dressings relevant to nutrition. Br. J. Nutr. 93: 257-266.
54. NEURATH, A.R. et al. 2004. Punica granatum (pomegranate) juice provides an HIV-1 entry inhibitor and candidate topical microbicide. BMC Infect. Dis. 4: 41 [http://www.biomedcentral.com/content/pdf/1471-2334-4-41.pdf].
55. SHATTOCK, R.J. & R.W. DOMS. 2002. AIDS models: microbicides could learn from vaccines. Nat. Med. 8: 425.
56. SKINNER, M. A. et al. 1988. Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res. Hum. Retrovir. 4: 187-197.
57. LAAL, S. & S. ZOLLA-PAZNER. 1993. Epitopes of HIV-1 glycoproteins recognized by the human immune system. In Immunochemistry of AIDS, Chemical Immunology, Vol. 56. E. Norrby, Ed.:91-111. Karger. Basel.
58. KWONO, P.D. et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659.
59. XIANO, S.H. et al. 2002. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 76: 9888-9899.
60. PANTOPHLET, R. et al. 2003. Fine mapping of the interaction of neutralizing and non-neutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77: 642-658.
61. WESTERVELT, P., H.E. GENDELMAN & L. RATNER. 1991. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc. Natl. Acad. Sci. USA 88: 3097-3101.
62. WESTERVELT, P. et al. 1992. Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. J. Virol. 66: 2577-2582.
63. RIZZUTO, C.D. et al. 1998. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280: 1949-1953.
64. CORMIER. E. G. & T. DRAGIC. 2002. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type I envelope slycoprotein interactions with the CCR5 coreceptor. J. Virol. 76: 8953-8957.
65. SUPHAPHIPHAT, P. et al. 2003. Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization. J. Virol. 77: 3832-3837.
66. LIU, S., S. FAN & Z. SUN. 2003. Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies. J. Mol. Model 9: 329-336.
67. ZHAO, Q., G. ALESPEITI & A.K. DEBNATH. 2004. A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5. Virology 326: 299-309.
68. LANOLEY, P. 2000. Why a pomegranate? BMJ 321: 1153-1154.
69. NAVARRO, V. et al. 1996. Antimicrobial evaluation of some plants used in Mexican traditional medicine for the treatment of infectious diseases. J. Ethnopharmacol. 53: 143-147.
70. LEE, J. & R.R. WATSON. 1988. Pomegranate: a role in health promotion and AIDS? In Nutrients and Foods in AIDS. R.R. Watson RR. Ed.:213-216. CRC. Boca Raton.
71. PRASHANTH, D., M.K. ASHA & A. AMIT. 2001. Antibacterial activity of Punica granatum. Fitoterapia 72: 171-173.
72. MOUHAJIR, F. et al. 2001. Multiple antiviral activities of endemic medicinal plants used by Berber peoples of Morocco. Pharm. Biol. 39: 364-374.
73. NEGI, P.S., G.K. JAYAPRAKASHA & B.S. JENA. 2003. Antioxidant and antimutagenic activities of pomegranate peel extracts. Food Chem. 80: 393-397.
74. GREENE. W.C. 2004. The brightening future of HIV therapeutics. Nat. Immunol. 5: 867-871.
75. POYRAZOGLU, E., V. GOEKMEN & N. ARTIK. 2002. Organic acids and phenolic compounds in pomegranates (Punica granatum L.) grown in Turkey. J. Food Composition and Analysis 15: 567-575.
76. MODULE 2: Phytochemicals (minerals, phytamins, and vitamins). 2003. [http://www.ars-grin.gov/duke/syllabus/module2.htm].
77. MAHMOOD, N. et al. 1993. Inhibition of HIV infection by caffeoylquinic acid derivatives. Antivir. Chem. Chemother. 4: 235-240.
78. MA, C. et al. 1998. Inhibitory effects of ursolic acid derivatives from cynomorium songaricum, and related triterpenes on human immunodeficiency viral protease. Phytother. Res. 12: S138-S142.
79. MAHMOOD, N. et al. 1996. The anti-HIV activity and mechanisms of action of pure compounds isolated from Rosa damascena. Biochem. Biophys. Res. Commun. 229: 73-79.
80. DETOMMASI, N. et al. 1998. Anti-HIV activity directed fractionation of the extracts of Margyricarpus setosus. Pharma. Biol. 36: 29-32.
81. ZHANG, J. et al. 1995. Antiviral activity of tannin from the pericarp of Punica granatum L. against genital Herpes virus in vitro. Zhongguo Zhong Yao Za Zhi 20: 556-8. 576.
82. LI, Y. et al. 2004. Antiviral activities of medicinal herbs traditionally used in Southern Mainland China. Phytother. Res. 18: 718-722.
83. Pomegranates could help in battle against AIDS. 1996. Reuters NewMedia. Inc. [http://www.aegis.com/news/re/1996/RE960310.html].
84. Medical breakthrough. 1996. British Muslims Monthly Survey IV (3),6. [http://artsweb.bham.ac.uk/bmms/1996/03March96.html#Medical%20breakthrough].
85. JASSIM, S.A.A., S.P. DENVER & G.S.A.B. STEWART. 1998. Antiviral or antifungal composition comprising an extract of pomegranate rind or other plants and method of use. US Patent 5,840,308. November 24, 1998.
86. SHEHADEH, A.A. 2000. Herbal extract composition and method with immune-boosting capability. US Patent 6,030,622. February 29, 2000.
87. JASSIM, S.A.A., S.P. DENYER & G.S.A.B. STEWART. 2001. Antiviral or antifungal composition and method. US Patent 6,187,316. February 2, 2001.
88. JASSIM, S.A.A. & S.P. DENYER. 2002. Antiviral or antifungal compositon and method. US Patent Application 20020064567. May 30, 2002.
89. HSU, S.-T. & A.M.J.J. BONVIN. 2004. Atomic insight into the CD4 binding-induced conformational changes in HIV-1 gp120. Proteins 55: 582-593.
90. NEURATH, A.R. et al. 1994. Tin protoporphyrin IX used in control of heme metabolism in humans effectively inhibits HIV-1 infection. Antivir. Chem. Chemother. 5: 322-330.
91. HAMMAR, L. et al. 1995. Lectin-mediated effects of HIV type 1 infection in vitro. AIDS Res. Hum. Retrovir. 11: 87-95.
92. VEAZEY, R.S. et al. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9: 343-346.
93. GARG, S. et al. 2001. Compendium of pharmaceutical excipients for vaginal formulations. Pharma. Techn. Drug Deliv. Sept. 14-24.
94. YAO, W.H. 2002. Adsorbent characteristics of porous starch. Starch/Starke 54: 260-263.
95. WHISTLER, R.L. 1991. Microporous granular starch matrix compositions. US Patent 4,985,082. January 15, 1991.
96. BERSET, C., H. CLERMONT & S. CHEVAL. 1995. Natural red colorant effectiveness as influenced by absorptive supports. J. Food Sci. 60: 858-861, 879.
97. STUTE, R. & H.U. WOELK. 1974. Interaction between starch and reactive dyes. New technique for the investigation of starch. II. Influence on fixation reaction of starch. Starch/Starke 26: 1-9.
98. SEGUCHI, M. 1986. Dye binding to the surface of wheat starch granules. Cereal Chem. 63: 518-520.
99. TOMASIK, P., Y.-J. WANG & J.L. JANE. 1995. Complexes of starch with low-molecular saccharides. Starch/Starke 47: 185-191.
100. ZHANG, G., M.D. MALADEN & B.R. HAMAKER. 2003. Detection of a novel three component complex consisting of starch, protein, and free fatty acids. J. Agric. Food Chem. 51:2801-2805.
101. JOHNSON, J.M., E.A. DAVIS & J. GORDON. 1990. Lipid binding of modified corn starches studies by electron spin resonance. Cereal Chem. 67: 236-240.
102. TOMAZIC-JEZIC, V.J., A.D. LUCAS & B.A. SANCHEZ. 2004. Binding and measuring natural rubber latex proteins on glove powder. J. Immunoassay Immunochem. 25: 109-123.
103. CONDE-PETIT, B. et al. 1998. Comparative charaterization of aqueous starch dispersions by light microscopy, rheometry, and iodine binding behavior. Starch/Starke 50: 184-192.
104. MOORE, J. et al. 2004. Development of fusion/entry inhibitors as topical microbicides. Presented at Microbicides 2004. London. March 28-31 2004. [http://www.microbicides2004.org.uk/progtue.html].
105. NEURATH, A.R. & N. STRICK. 2003. Biodegradable microbicidal vaginal barrier device. US Patent 6,572,875. June 3, 2003.
106. NEURATH, A.R., N. STRICK & S. JIANG. 1992. Synthetic peptides and anti-peptide antibodies as probes to study interdomain interactions involved in virus assembly: The envelope of the human immunodeficiency virus (HIV-1). Virology 188: 1-13.
107. KRAULIS, P. J. 1991. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Cryst. 24: 946-950.
108. BACON, D.J. & W.F. ANDERSON. 1988. A fast algorithm for rendering space-filling molecule pictures. J. Mol. Graphics 6: 219-220.
109. MERRITT, E.A. & D.J. BACON. 1997. Raster3D: photorealistic molecular graphics. Meth. Enzymol. 277: 505-524.